Merck, Inc.
🇺🇸United States
Consistency Lots Vaccine Study (V260-009)
Phase 3
Completed
- Conditions
- Rotavirus Infections
- Interventions
- Biological: PlaceboBiological: rotavirus vaccine, live, oral, pentavalent
- First Posted Date
- 2004-09-27
- Last Posted Date
- 2015-10-05
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 793
- Registration Number
- NCT00092456
Study of an Investigational Vaccine in Healthy Infants in Taiwan (V441-001)(COMPLETED)
Phase 3
Completed
- Conditions
- PoliomyelitisTetanusPertussisHepatitis BDiphtheria
- First Posted Date
- 2004-09-27
- Last Posted Date
- 2015-10-07
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 151
- Registration Number
- NCT00092469
Study of MK0869 for the Prevention of Chemotherapy-Induced Nausea and Vomiting (0869-071)(COMPLETED)
Phase 3
Completed
- Conditions
- VomitingNauseaBreast Neoplasms
- First Posted Date
- 2004-09-24
- Last Posted Date
- 2017-05-05
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 820
- Registration Number
- NCT00092196
A Study of MK0217A and Dietary Supplement in Men and Postmenopausal Women With Osteoporosis (0217A-227)
Phase 3
Completed
- Conditions
- OsteoporosisVitamin D Deficiency
- First Posted Date
- 2004-09-24
- Last Posted Date
- 2014-11-11
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 652
- Registration Number
- NCT00092079
An Investigational Drug for the Prevention of Chemotherapy-Induced Nausea and Vomiting (MK-0869-071)
Phase 4
Completed
- Conditions
- NauseaBreast NeoplasmsVomiting
- First Posted Date
- 2004-09-24
- Last Posted Date
- 2017-05-05
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 866
- Registration Number
- NCT00092183
An Investigational Agent for the Treatment of Complicated Intra-Abdominal Infections or Acute Pelvic Infections (0826-038)
Phase 2
Completed
- Conditions
- InfectionsPelvic Infections
- First Posted Date
- 2004-09-24
- Last Posted Date
- 2017-02-17
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 100
- Registration Number
- NCT00092170
Oral SAHA (Suberoylanilide Hydroxamic Acid) in Advanced Cutaneous T-cell Lymphoma (0683-001)
Phase 2
Completed
- Conditions
- Cutaneous T-cell LymphomaSezary SyndromeMycosis Fungoides
- First Posted Date
- 2004-09-14
- Last Posted Date
- 2017-04-05
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 74
- Registration Number
- NCT00091559
Temozolomide Versus Dacarbazine in Stage IV Metastatic Melanoma (Study P03267)
- First Posted Date
- 2004-09-14
- Last Posted Date
- 2017-06-06
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 859
- Registration Number
- NCT00091572
2 Doses of an Approved Drug Being Studied for a New Indication for the Prevention of Postoperative Nausea and Vomiting (0869-090)(COMPLETED)
Phase 3
Completed
- Conditions
- Postoperative Nausea and Vomiting
- First Posted Date
- 2004-08-27
- Last Posted Date
- 2017-05-05
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 805
- Registration Number
- NCT00090155
Aprepitant for the Prevention of Chemotherapy Induced Nausea and Vomiting (CINV) Associated With Highly Emetogenic Chemotherapy (0869-801)(COMPLETED)
Phase 4
Completed
- Conditions
- NauseaVomiting
- First Posted Date
- 2004-08-27
- Last Posted Date
- 2017-04-24
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 477
- Registration Number
- NCT00090207
© Copyright 2025. All Rights Reserved by MedPath